Skip to content

Clinical study on the precision treatment of recurrent spontaneous abortion based on PK/PD/PG and thromboelastography

Clinical study on the precision treatment of recurrent spontaneous abortion based on PK/PD/PG and thromboelastography

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074734
Enrollment
Unknown
Registered
2023-08-15
Start date
2023-08-15
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent spontaneous abortion

Interventions

Recurrent aborted pregnancy and :NA
healthy pregnancy:NA

Sponsors

Hainan General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for recurrent aborted pregnancies: pregnant RSA patients attending obstetric clinics (2 or more consecutive miscarriages < 28 weeks of gestation). Inclusion criteria: ? the chromosomes of both spouses were normal; ? All endocrine indicators of pregnant women are normal; ? Pregnant women have no history of allergies and defects; ? Pregnant women have normal liver function and have not used oral contraceptives, anticoagulants, and drugs that promote fibrinolytic drugs have an effect on fetal development in the past 3 months. Inclusion criteria for healthy pregnancy: women with healthy pregnancy status.

Exclusion criteria

Exclusion criteria: The exclusion criteria for recurrent aborted pregnancy were: (1) reproductive tract infection; ? uterine malformation; ? Routine examination of male semen abnormalities. Exclusion criteria for healthy pregnancy: pregnant women with thrombotic diseases, hypertension, diabetes, systemic lupus erythematosus, liver and kidney function impairment and other diseases, with a history of abnormal pregnancy, and diseases that may affect the balance of the body's coagulation and fibrolysis system.

Design outcomes

Primary

MeasureTime frame
D-dimer;Blood clot susceptibility gene;Anti-factor Xa activity;Thromboelastography;

Countries

China

Contacts

Public ContactDanna Wu

Hainan General Hospital

wudannachangchang@163.com+86 188 7616 0135

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026